Publication:
Assessment of Quantiferon®-CMV and Immuknow® Assays in CMV-seropositive Lung Transplant Recipients to Stratify Risk of CMV Infection.

dc.contributor.authorMonforte, Victor
dc.contributor.authorSintes, Helena
dc.contributor.authorUssetti, Piedad
dc.contributor.authorCastejon, Raquel
dc.contributor.authorPérez, Virginia Luz
dc.contributor.authorLaporta, Rosalia
dc.contributor.authorSole, Amparo
dc.contributor.authorCifrian, Jose Manuel
dc.contributor.authorMarcos, Pedro J
dc.contributor.authorRedel, Javier
dc.contributor.authorLos-Arcos, Ibai
dc.contributor.authorSaez, Berta
dc.contributor.authorAlonso, Rodrigo
dc.contributor.authorRosado, Silvia
dc.contributor.authorEscriva, Juan
dc.contributor.authorIturbe, David
dc.contributor.authorOvalle, Juan Pablo
dc.contributor.authorVaquero, Jose Manuel
dc.contributor.authorRevilla, Eva
dc.contributor.authorMendoza, Alberto
dc.contributor.authorGomez-Olles, Susana
dc.contributor.funderRoche Farma SA
dc.date.accessioned2023-05-03T14:45:16Z
dc.date.available2023-05-03T14:45:16Z
dc.date.issued2021
dc.description.abstractLung transplant recipients (LTR) are at significantly higher risk for cytomegalovirus (CMV) infection compared to recipients of other solid organ transplants (SOT), with both the direct and indirect effects of CMV infection contributing to increased morbidity and mortality in this population. Current guidelines recommend universal antiviral prophylaxis for a duration of 6 to 12 months depending on the recipient’s CMV serostatus. However, prolonged antiviral use is associated with adverse effects, often necessitating early discontinuation of prophylaxis. To address this, several authors have proposed the use of the Quantiferon®-CMV assay as a tool to stratify the risk of CMV disease in SOT recipients, which could facilitate more personalized prophylaxis strategies. Nevertheless, its utility in CMV-seropositive lung transplant recipients (LTR+), who represent 80–90% of LTRs in Spain, remains unclear. Notably, it has been reported that up to 20% of LTR+ patients with high Quantiferon®-CMV responses still develop CMV infection. A potential explanation for this paradox is that high levels of immunosuppression may suppress other critical immune pathways involved in CMV control. The overall intensity of immunosuppression can be evaluated using the Immuknow® assay. Based on this, we hypothesized that the risk of CMV infection in LTR+ patients could be more accurately stratified by combining results from both the Quantiferon®-CMV and Immuknow® assays.
dc.description.versionNo
dc.identifier.citationMonforte V, Sintes H, Ussetti P, Castejón R, Pérez VL, Laporta R, et al. Assessment of Quantiferon®-CMV and Immuknow® Assays in CMV-seropositive Lung Transplant Recipients to Stratify Risk of CMV Infection. Arch Bronconeumol. 2022 Aug;58(8):614-617. English, Spanish
dc.identifier.doi10.1016/j.arbres.2021.10.002
dc.identifier.essn1579-2129
dc.identifier.pmid35312499
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.arbres.2021.10.002
dc.identifier.urihttp://hdl.handle.net/10668/22001
dc.issue.number8
dc.journal.titleArchivos de bronconeumologia
dc.journal.titleabbreviationArch Bronconeumol
dc.language.isoen
dc.language.isoes
dc.organizationHospital Universitario Reina Sofía
dc.page.number614-617
dc.provenanceRealizada la curación de contenido 13/06/2025
dc.publisherElsevier
dc.pubmedtypeCase Reports
dc.relation.publisherversionhttp://www.archbronconeumol.org/en/linksolver/ft/pii/S0300-2896(21)00345-8
dc.rights.accessRightsRestricted Access
dc.subjectTransplant Recipients
dc.subjectSpain
dc.subjectCytomegalovirus Infections
dc.subjectOrgan Transplantation
dc.subjectImmunosuppression Therapy
dc.subject.decsInfecciones
dc.subject.decsAntivirales
dc.subject.decsTerapia de inmunosupresión
dc.subject.decsSerología
dc.subject.decsReceptores de trasplantes
dc.subject.meshAntiviral Agents
dc.subject.meshCytomegalovirus Infections
dc.subject.meshHumans
dc.subject.meshKidney Transplantation
dc.subject.meshLung
dc.subject.meshTransplant Recipients
dc.titleAssessment of Quantiferon®-CMV and Immuknow® Assays in CMV-seropositive Lung Transplant Recipients to Stratify Risk of CMV Infection.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number58
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format